Reimbursements
Column {data-width=650}
Top vendors
Gilead
Top product reimbursed by State
| State | Label | Vendor | Medicaid Paid |
|---|---|---|---|
| AK | MAVYRET | AbbVie Inc. | $7,526,463 |
| AL | FOCALIN XR | Novartis Pharmaceuticals Corporation | $26,580,202 |
| AR | FOCALIN XR | Novartis Pharmaceuticals Corporation | $27,441,369 |
| AZ | MAVYRET | AbbVie Inc. | $39,361,497 |
| CA | ABILIFY | Otsuka America Pharmaceuticals Inc. | $402,645,829 |
| CO | HUMIRA PEN | AbbVie Inc. | $33,238,648 |
| CT | EPCLUSA 4 | Gilead Sciences, Inc. | $38,064,165 |
| DC | GENVOYA TA | Gilead Sciences, Inc. | $27,703,403 |
| DE | REMICADE | Janssen Biotech, Inc. | $441,530 |
| FL | GENVOYA | Gilead Sciences, Inc. | $69,940,884 |
| GA | METHYLPHEN | SpecGx LLC | $45,932,383 |
| HI | INVEGA SUS | Janssen Pharmaceuticals, Inc. | $8,240,455 |
| IA | FOCALIN XR | Novartis Pharmaceuticals Corporation | $7,343,680 |
| ID | LATUDA | Sunovion Pharmaceuticals Inc. | $6,872,713 |
| IL | HUMIRA - A | AbbVie Inc. | $79,791,099 |
| IN | Lyrica (pr | Parke-Davis Div of Pfizer Inc | $39,690,429 |
| KS | INVEGA SUS | Janssen Pharmaceuticals, Inc. | $8,030,921 |
| KY | MAVYRET | AbbVie Inc. | $58,730,254 |
| LA | VYVANSE | Shire LLC | $41,284,359 |
| MA | SUBOXONE 8 | Indivior Inc. | $73,358,404 |
| MD | GENVOYA TA | Gilead Sciences, Inc. | $36,075,640 |
| ME | SUBOXONE | Indivior Inc. | $13,540,720 |
| MI | LATUDA | Sunovion Pharmaceuticals Inc. | $78,752,958 |
| MN | HUMIRA PEN | AbbVie Inc. | $35,255,482 |
| MO | LATUDA | Sunovion Pharmaceuticals Inc. | $37,356,044 |
| MS | NOVOLOG 10 | Novo Nordisk | $9,520,571 |
| MT | HUMIRA 40 | AbbVie Inc. | $7,327,608 |
| NC | VYVANSE | Shire LLC | $54,168,043 |
| ND | NOVOLOG 10 | Novo Nordisk | $3,437,474 |
| NE | FOCALIN XR | Novartis Pharmaceuticals Corporation | $8,605,088 |
| NH | SUBOXONE | Indivior Inc. | $4,861,090 |
| NJ | HUMIRA - A | AbbVie Inc. | $48,746,835 |
| NM | MAVYRET 10 | AbbVie Inc. | $33,539,109 |
| NV | HUMIRA - A | AbbVie Inc. | $13,699,434 |
| NY | GENVOYA | Gilead Sciences, Inc. | $116,342,318 |
| OH | HUMIRA - A | AbbVie Inc. | $103,591,345 |
| OK | HUMIRA - A | AbbVie Inc. | $13,132,125 |
| OR | HUMIRA - A | AbbVie Inc. | $30,846,525 |
| PA | MAVYRET 10 | AbbVie Inc. | $126,225,742 |
| RI | HUMIRA - A | AbbVie Inc. | $10,941,014 |
| SC | VYVANSE | Shire LLC | $24,309,032 |
| SD | ARANESP (d | Amgen Inc | $2,669,794 |
| TN | VYVANSE | Shire LLC | $31,885,976 |
| TX | NORDITROPI | Novo Nordisk | $60,011,161 |
| UT | INVEGA SUS | Janssen Pharmaceuticals, Inc. | $7,215,932 |
| VA | ONDANSETRO | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | $22,637,386 |
| VT | Suboxone S | Indivior Inc. | $17,445,893 |
| WA | HUMIRA - A | AbbVie Inc. | $69,119,825 |
| WI | HUMIRA - A | AbbVie Inc. | $52,716,986 |
| WV | SUBOXONE 8 | Indivior Inc. | $37,003,078 |
| WY | HUMIRA - A | AbbVie Inc. | $1,508,235 |
Reimbursement breakdown by type of care
Column
Top 15 drugs (in dollar amount) reimbursed by Medicaid across all States
| Label | Medicaid Paid | Non-Medicaid Paid | Total Reimbursements |
|---|---|---|---|
| HUMIRA 40 | $1,707,478,371 | $11,580,403 | $1,719,058,774 |
| MAVYRET 10 | $1,657,688,346 | $1,983,794 | $1,659,672,140 |
| METHYLPHEN | $1,165,440,281 | $32,921,367 | $1,198,361,648 |
| INVEGA SUS | $1,161,877,422 | $12,973,868 | $1,174,851,290 |
| FLOVENT HF | $1,148,514,719 | $20,344,059 | $1,168,858,778 |
| VENTOLIN H | $1,037,910,134 | $6,082,060 | $1,043,992,194 |
| GENVOYA TA | $1,022,565,800 | $4,872,160 | $1,027,437,960 |
| SYMBICORT | $949,856,775 | $9,811,423 | $959,668,198 |
| UNKNOWN | $907,815,652 | $81,628,364 | $989,444,016 |
| HUMALOG 10 | $860,198,372 | $23,581,226 | $883,779,598 |
| SUBOXONE 8 | $846,395,095 | $5,353,623 | $851,748,718 |
| HUMIRA - A | $839,869,552 | $7,472,786 | $847,342,338 |
| HUMIRA PEN | $815,359,288 | $4,132,718 | $819,492,006 |
| PROAIR HFA | $797,866,520 | $11,395,903 | $809,262,423 |
| GENVOYA | $790,877,220 | $4,628,794 | $795,506,014 |
Clustering check
Column
Correlation-based clustering
Cluster tendency
Determine k: WSS method
Determine k: Silhouette method
Cluster analysis
Column {data-width=350}
Clusters by State (k = 4)
k-means table
| Cluster | Medicaid Paid | Prescriptions | Units reimbursed | Total reimbursed | Fee-for-Service | Managed Care |
|---|---|---|---|---|---|---|
| 1 | $248,566,206 | 3,237,227 | 207,890,170 | $267,367,206 | 9,899 | 13,406 |
| 2 | $5,999,992,267 | 87,479,007 | 5,296,480,177 | $7,244,277,296 | 42,666 | 63,656 |
| 3 | $996,511,064 | 10,354,094 | 630,818,099 | $1,032,195,797 | 32,570 | 3,594 |
| 4 | $1,799,141,612 | 22,823,271 | 1,364,962,160 | $1,857,138,798 | 17,414 | 41,217 |
Column {data-width=350}
Clusters by State (k = 2)
k-means table
| Cluster | Medicaid Paid | Prescriptions | Units reimbursed | Total reimbursed | Fee-for-Service | Managed Care |
|---|---|---|---|---|---|---|
| 1 | $4,076,952,128 | 53,140,704 | 3,306,489,368 | $4,560,281,645 | 26,586 | 54,515 |
| 2 | $727,880,351 | 9,031,114 | 535,688,923 | $757,273,729 | 17,344 | 17,648 |
Model
Random Forest model
parsnip model object
Ranger result
Call:
ranger::ranger(formula = formula, data = data, mtry = ~5, num.trees = ~200, seed = ~5462, importance = ~"impurity", respect.unordered.factors = ~TRUE, num.threads = 1, verbose = FALSE)
Type: Regression
Number of trees: 200
Sample size: 11250
Number of independent variables: 12
Mtry: 5
Target node size: 5
Variable importance mode: impurity
Splitrule: variance
OOB prediction error (MSE): 15871955197
R squared (OOB): 0.6271315 Important variables based on node impurity reduction
Model predictions
